Uloric
Total Payments
$5.5M
Transactions
32,932
Doctors
11,675
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $170,006 | 744 | 474 |
| 2018 | $613,560 | 11,964 | 4,537 |
| 2017 | $4.7M | 20,224 | 9,459 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.5M | 1,744 | 82.2% |
| Food and Beverage | $349,760 | 30,242 | 6.4% |
| Consulting Fee | $337,138 | 35 | 6.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $242,425 | 144 | 4.4% |
| Travel and Lodging | $46,093 | 228 | 0.8% |
| Education | $4,490 | 539 | 0.1% |
Payments by Type
Research
$4.5M
1,744 transactions
General
$979,906
31,188 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Development Center Americas, Inc. | $4.0M | 6 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Pharmaceuticals U.S.A., Inc. | $468,724 | 8 |
| Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo | Takeda Development Center Americas, Inc. | $17,355 | 0 |
| Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo | Takeda Development Center Americas, Inc. | $9,172 | 0 |
| Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo | Takeda Pharmaceuticals U.S.A., Inc. | $6,960 | 0 |
| Ph2 Double Blind Pbo controlled study to assess the effect of feb 80mg QD & feb 30mg BID compared to Placebo on ABPM in subjects with hyperuricemia & HT | Takeda Pharmaceuticals U.S.A., Inc. | $3,946 | 0 |
| Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo | Takeda Pharmaceuticals U.S.A., Inc. | $3,629 | 0 |
| Early Gout Damage | Takeda Pharmaceuticals U.S.A., Inc. | $2,663 | 0 |
Top Doctors Receiving Payments for Uloric
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $4.4M | 1,706 |
| , MD | Hypertension Specialist | Farmington, CT | $142,110 | 58 |
| , M.D | Infectious Disease | Rahway, NJ | $92,426 | 6 |
| , MD | Rheumatology | Burr Ridge, IL | $42,348 | 37 |
| , MD | Cardiovascular Disease | New York, NY | $41,391 | 22 |
| , MD | Rheumatology | Gainesville, FL | $31,382 | 38 |
| , MD | Rheumatology | New York, NY | $28,653 | 17 |
| , MD, PHD | Rheumatology | Boston, MA | $24,561 | 51 |
| , M.D | Rheumatology | Fayetteville, NC | $15,288 | 19 |
| , MD | Rheumatology | Concord, NC | $13,455 | 11 |
| , MD | Neurological Surgery | Grand Rapids, MI | $13,447 | 22 |
| , M.D | Rheumatology | Mobile, AL | $11,486 | 22 |
| , M.D | Nephrology | Washington, PA | $11,342 | 18 |
| , M.D | Rheumatology | Fullerton, CA | $10,039 | 13 |
| , M.D | Nephrology | New York, NY | $9,440 | 10 |
| , M.D | Student in an Organized Health Care Education/Training Program | Evanston, IL | $9,156 | 10 |
| , MD | Rheumatology | Tustin, CA | $8,226 | 11 |
| , M.D | Rheumatology | San Antonio, TX | $7,829 | 7 |
| , DO | Rheumatology | Austin, TX | $7,648 | 25 |
| , MD | Rheumatology | Indianapolis, IN | $7,382 | 9 |
| , MD | Internal Medicine | Redwood City, CA | $6,479 | 9 |
| , M.D | Internal Medicine | Lake Providence, LA | $5,591 | 13 |
| , M.D | Specialist | Fayetteville, AR | $4,983 | 4 |
| , M.D | Rheumatology | Dunedin, FL | $4,800 | 9 |
| , M.D | Rheumatology | Berkeley, CA | $4,632 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.5M
- Total Doctors 11,675
- Transactions 32,932
About Uloric
Uloric is a drug associated with $5.5M in payments to 11,675 healthcare providers, recorded across 32,932 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Development Center Americas, Inc..
Payment data is available from 2017 to 2019. In 2019, $170,006 was paid across 744 transactions to 474 doctors.
The most common payment nature for Uloric is "Unspecified" ($4.5M, 82.2% of total).
Uloric is associated with 8 research studies, including "Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia" ($4.0M).